The pharma giant is paying Isis $31 million up front along with an unspecified package of milestones for new antisense drugs that can hit 5 cancer drugs. And AstraZeneca is snagging the rights to one of Isis' early-stage drugs, ISIS-STAT3Rx, for advanced lymphomas.
Covidien is expanding the adoption of its Nellcor blood oxygenation monitor, announcing a deal with GE Healthcare that will integrate its devices with GE's Giraffe and Panda infant warmers.
GlaxoSmithKline will take advantage of the ubiquitous mobile phone to increase vaccination rates in Africa. The pharma giant is teaming up with British mobile phone group Vodafone to use text messages to alert mothers about the availability of vaccinations and help them to schedule appointments.
Preclinical research into cancer immunotherapy at the University of Texas MD Anderson Cancer Center has caught the attention GlaxoSmithKline. This has resulted in the signing of a research collaboration and licensing agreement that could be worth $335 million in upfront, milestone and royalty payments.
Less than a year after Biogen Idec inked its first development pact with the antisense experts at Isis Pharmaceuticals, the big biotech has come back to the bargaining table to sign off on their third deal, with Biogen paying $30 million upfront and promising up to $200 million more in milestones for each of three new programs aimed at neurological diseases and neuromuscular disorders.
Alimera Sciences is facing an uphill battle getting its chronic diabetic macular edema drug on shelves in Europe, and now the company has recruited Quintiles to manage the European launch of Iluvien.
Amid budget-slashing and restructuring, AMRI has some good news to report: The CRO has re-signed with GE Healthcare to supply materials for diagnostic imaging, locking down its biggest commercial supply client through 2016.
Despite pretty much running out of cash this summer, Marina Biotech is still struggling along, touting Phase I results from licensee ProNAi Therapeutics.
After a delay in its patch program, Australian drug delivery company Phosphagenics has provided an update on its work on its transdermal opioid franchise, including the latest developments on its lead oxycodone patch.
The FDA is joining up with the Medical Device Innovation Consortium, a public-private outfit uniting CDRH experts with the likes of Medtronic and Boston Scientific, all in the name of advancing regulatory science to speed the path of investigational devices.